When choosing how to reduce the risk of stroke, a clinician uses tools to estimate the risk of stroke and serious bleeding ...
Some clinicians prefer aspirin when balancing bleeding risk with the indication for an anticoagulant, Barnes said, reasoning ...
A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...
Researchers have found in a cohort study that patients with atrial fibrillation (AF) receiving a factor Xa inhibitor and ...
The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...
Heart disease is the leading cause of death in the U.S., a balanced diet and exercise can help you live a healthy life.
Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF
Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...
Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.
1d
GlobalData on MSNNovartis signs agreement to acquire Anthos for $925m upfrontNovartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...
Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...
Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...
Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results